(Reuters) – Drugmaker AbbVie Inc has entered an agreement to develop and sell Chinese biotech company I-Mab’s lead cancer drug, the companies said on Friday.
AbbVie will pay I-Mab $180 million in upfront payment and an additional $1.74 billion in milestone payments for lemzoparlimab, the companies said.
(Reporting by Trisha Roy in Bengaluru; Editing by Arun Koyyur)
